Progress in the treatment of triple negative breast cancer with sacituzumab govitecan

VernacularTitle:戈沙妥珠单抗治疗三阴性乳腺癌的研究进展
Author: Mengchao WANG ¹ ; Liwei CHEN ; Fanming KONG
Author Information

1. 天津中医药大学第一附属医院肿瘤科　国家中医针灸临床医学研究中心，天津　300000
Keywords: Triple negative breast neoplasms; Clinical study; Sacituzumab govitecan
From: Journal of International Oncology 2022;49(10):619-622
CountryChina
Language:Chinese
Abstract: Triple-negative breast cancer is a subtype of invasive breast cancer, accounting for about 15% of all breast cancers. Its clinical treatment is relatively difficult, prone to recurrence and metastasis, with a short median survival and poor prognosis. Sacituzumab govitecan is the first approved antigen-coupled drug targeting trophoblast surface antigen 2 in the world. It has significant clinical efficacy, high safety and less adverse reactions, which brings new hope to the treatment of triple-negative breast cancer.